Digital gangrene due to dopamine infusion- a case report

Authors

  • M.M. Prabhu
  • S.M. Prabhu
  • P. Mishra
  • S. Palaian

DOI:

https://doi.org/10.66344/jpad.15.2.2005.639

Keywords:

Dopamine, gangrene, ischemia, shock

Abstract

Dopamine is a vasopressor agent for the treatment of shock and hypotension in patients whodo not respond to plasma volume expansion. Use of dopamine is associated with severeperipheral ischemia, particularly in patients in whom the peripheral circulation is alreadyimpaired. We describe a case of digital gangrene due to intravenous dopamine infusion in a45-year-old man who did not have any predisposing factor. The patient developed digitalgangrene within 24 hours of starting intravenous dopamine. Dopamine is one of thecommonly used vasopressor agents in the treatment of shock and hypotension and measuresshould be taken to detect the possibility of the development of gangrene based on thepredisposing factor and if gangrene occurs, immediate steps should be taken for managementof the reaction.

References

McEvoy GK, Miller J, Litvak K et al.,

eds. AHFS Drug Information. New

York: American Society of Health-

System Pharmacists; 2003.

Park JY, Kanzler M, Swetter SM.

Dopamine-associated symmetric

peripheral gangrene. Arch Dermatol

; 133: 247-9.

Sweetman SC, ed. Martindale The

Complete Drug Reference, 33rd edition.

London: Pharmaceutical Press; 2002.

Dukes MNG, Aronson JK, ed. Meyler’s

Side Effects of Drugs, 14th edition.

Amsterdam: Elsevier; 2000.

Gibbs NM, Oh TE. Nitroglycerine

ointment for dopamine induced

peripheral digital ischemia. Lancet

; 2: 290.

Downloads

Published

2016-12-28

How to Cite

1.
Prabhu M, Prabhu S, Mishra P, Palaian S. Digital gangrene due to dopamine infusion- a case report. J Pak Assoc Dermatol [Internet]. 2016Dec.28 [cited 2026Apr.22];15(2):197-9. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/639

Issue

Vol. 15 No. 2 (2005): April - June

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.